BioSig Technologies Welcomes the Creation of New Bioelectronic Medicine Alliance
November 18 2019 - 7:52AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or “The
Company”), a medical technology company developing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals, today announced that the Company supported the launch of
the Alliance for Advancing Bioelectronic Medicine (AABM), an
independent network of professionals united to support
bioelectronic medicine. The alliance grew out of an invitation-only
roundtable and working group that BioSig organized earlier this
year, at which a distinguished group of researchers, entrepreneurs,
and healthcare experts agreed on the need for a collaborative
effort to create a shared vision for bioelectronic medicine.
“BioSig is proud of our role in the conception and launch of
this important new alliance, which we believe will provide critical
value to the bioelectronic medicine field,” said Kenneth L.
Londoner, Founder, CEO, and Chairman of BioSig Technologies. “We
look forward to working with the alliance and its members to
articulate the value of bioelectronic medicine, catalyze meaningful
cross-sector collaboration, and engage new audiences. These goals
are vital to driving the field’s progress and impact on patients’
lives across disease areas.”
The Alliance for Advancing Bioelectronic Medicine aims to play a
unique convening role, mobilizing patients, physicians, and other
stakeholders to advocate for the field, and increasing awareness
among audiences that are important for the field’s growth,
including policymakers, investors, media, and the general public.
Its steering committee includes experts with experience at the Mayo
Clinic, the Heart Rhythm Society, the European Heart Rhythm
Association, The Feinstein Institute, RAND Corporation, Battelle,
Imperial College London, and Sheba Medical Center.
“BioSig’s leadership and support have helped to connect
bioelectronic medicine experts from diverse areas of the field,
which has led to our forming the Alliance for Advancing
Bioelectronic Medicine,” said Dr. Hein Heidbuchel, a founding
member of AABM and Professor and Chair of Cardiology, Anwerp
University and President of the European Heart Rhythm Association.
“We’ve seen impressive scientific and medical progress in
bioelectronic medicine in recent years, but what has been missing
is a compelling story that builds understanding and support for
this field across a wide range of relevant audiences. We look
forward to working together and contributing to the growth of this
promising field.” About BioSig Technologies BioSig
Technologies is a medical technology company developing a
proprietary biomedical signal processing platform designed to
improve the electrophysiology (EP) marketplace (www.biosig.com).
Led by a proven management team and a veteran Board of Directors,
BioSig Technologies is preparing to commercialize its PURE EP(tm)
System. The technology has been developed to address an unmet need
in a large and growing market.
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory. The system is indicated for use under the supervision
of licensed healthcare practitioners who are responsible for
interpreting the data. This novel cardiac signal acquisition and
display system is engineered to assist electrophysiologists in
clinical decision-making during electrophysiology procedures in
patients with abnormal heart rates and rhythms. BioSig’s ultimate
goal is to deliver technology to improve upon catheter ablation
treatments for the prevalent and potentially deadly arrhythmias,
Atrial Fibrillation and Ventricular Tachycardia. BioSig has
partnered with Minnetronix on technology development and received
FDA 510(k) clearance for the PURE EP(tm) System in August 2018.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (ii) difficulties in
obtaining financing on commercially reasonable terms; (iii) changes
in the size and nature of our competition; (iv) loss of one or more
key executives or scientists; and (v) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Contact:
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x119
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024